Pfizer Inc. / InnoPharma, Inc.

Sterile Injectable Pharmaceuticals (Oncology & CNS)

$7.0B Global sterile injectables market 2014 (>$7B) · 73 Pfizer SI portfolio post-deal (vs. 44 pre-deal)

Disease Overview

Sterile injectables are complex parenteral drug formulations — including pen, depot and ophthalmic delivery systems — used heavily in hospital oncology and CNS care. They are difficult and capital-intensive to manufacture, leading to chronic shortages (~80% of FDA-tracked drug shortages in the early 2010s) and creating a defensible niche for specialty manufacturers.

Competitive Landscape

The 2014 sterile injectables market was a >$7B segment marked by chronic shortages and consolidation. InnoPharma slotted Pfizer into a fast-growing complex-generics niche populated by Hospira (which Pfizer would acquire for $17B in 2015), Mylan, Hikma, Sandoz and Fresenius Kabi. InnoPharma's 10 marketed generics, 19 ANDA filings and 30+ pipeline injectables — including hard-to-make oncology and CNS molecules — expanded Pfizer Injectables' portfolio from 44 to 73 products and added pen and depot delivery capabilities. Per Pfizer, the InnoPharma submitted-product set addressed ~$5B of branded reference revenue with another ~$7B in pipeline value. The deal was widely read as a pre-Hospira tuck-in: it gave Pfizer's Global Established Pharma unit a complex-generics development engine in NJ, complementing Hospira's manufacturing scale that arrived a year later. It also signaled that Big Pharma had concluded sterile injectable generics — long viewed as low-margin commodity — were now structurally attractive due to manufacturing barriers to entry and persistent shortage-driven pricing.